Blood sensors are expanding beyond Alzheimer’s disease because the same pathological proteins that accumulate in Alzheimer’s brains also drive other neurodegenerative diseases—and researchers have discovered that detecting these markers in blood can identify multiple conditions with similar accuracy. A single blood test can now measure phosphorylated tau, phosphorylated alpha-synuclein, and neurofilament light chain levels, each of which correlates not just with Alzheimer’s but with Parkinson’s disease, Lewy body dementia, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS). Companies like C2N Diagnostics, Eli Lilly, and Roche are investing in multi-disease blood biomarker platforms precisely because the science works: the same proteins appear in circulation across multiple brain disorders, making a single blood draw potentially diagnostic for several conditions.
This shift reflects a fundamental change in how neurology approaches diagnosis. For decades, distinguishing between Alzheimer’s, Parkinson’s, Lewy body dementia, and frontotemporal dementia required years of clinical observation, PET imaging, or—most definitively—brain autopsy. Today, blood biomarkers can often make these distinctions within months of symptom onset, catching diseases at earlier, more treatable stages. The commercial expansion is not hype; it is a direct response to clinical need and scientific validation across patient populations.
Table of Contents
- HOW SHARED PROTEIN PATHWAYS OPENED BLOOD TESTING ACROSS BRAIN DISEASES
- THE BLOOD BIOMARKERS DETECTING PARKINSON’S, FRONTOTEMPORAL DEMENTIA, AND BEYOND
- HOW BLOOD SENSORS ARE CHANGING EARLY DETECTION AND PATIENT OUTCOMES
- WHAT BLOOD TESTS CAN AND CANNOT DO: INTEGRATING BLOOD BIOMARKERS INTO CLINICAL CARE
- THE MAJOR CHALLENGES: STANDARDIZATION, ACCESS, AND TEST VALIDITY ACROSS POPULATIONS
- HOW INSURANCE AND ACCESSIBILITY SHAPE WHO CAN GET TESTED
- CURRENT CLINICAL USE: WHERE BLOOD BIOMARKERS FIT IN NEUROLOGY TODAY
HOW SHARED PROTEIN PATHWAYS OPENED BLOOD TESTING ACROSS BRAIN DISEASES
All neurodegenerative diseases involve misfolded proteins that spread through neural tissue. Alzheimer’s disease involves amyloid-beta and phosphorylated tau; Parkinson’s and Lewy body dementia involve alpha-synuclein; frontotemporal dementia involves tau and TDP-43. When these proteins misfold and accumulate, they trigger neuroinflammation and neuronal death, and fragments of these proteins leak into the bloodstream. Because the fundamental mechanism is shared—protein misfolding, seeding, spread, and neurodegeneration—researchers realized that blood biomarkers developed for Alzheimer’s could be adapted and refined to detect other diseases.
The key insight came from studying people with multiple pathologies. Many patients who present clinically with one disease actually have brain pathology from two or three diseases at autopsy—for example, Alzheimer’s tau plus Lewy body pathology. Blood biomarkers can now identify these mixed presentations, which traditional clinical diagnosis often missed. This means a patient presenting with memory loss and movement problems can be tested for both Alzheimer’s and Parkinson’s pathology simultaneously, rather than undergoing years of clinical trial-and-error.
THE BLOOD BIOMARKERS DETECTING PARKINSON’S, FRONTOTEMPORAL DEMENTIA, AND BEYOND
Phosphorylated alpha-synuclein (p-syn) in blood is now recognized as a marker of Lewy body disease (Parkinson’s disease, Lewy body dementia, and pure autonomic failure all share alpha-synuclein pathology). studies from 2023 and 2024 show that p-syn levels correlate with cognitive decline in Parkinson’s disease and can help distinguish Lewy body dementia from Alzheimer’s dementia in patients with overlapping symptoms. The specificity is high enough that a positive p-syn result combined with clinical presentation can substantially narrow the diagnostic field, eliminating months of uncertainty.
Neurofilament light chain (NfL) is a marker of axonal damage that appears elevated in multiple neurodegenerative diseases, including ALS, frontotemporal dementia, and progressive supranuclear palsy. Unlike tau or alpha-synuclein, NfL is not disease-specific but rather tracks the rate of neuronal death. This makes it useful as a progression marker—patients with rapidly rising NfL levels are experiencing faster neurodegeneration and may benefit from earlier intervention or more aggressive monitoring. However, elevated NfL alone cannot tell you which disease a patient has; it must be combined with other markers and clinical data.
HOW BLOOD SENSORS ARE CHANGING EARLY DETECTION AND PATIENT OUTCOMES
Early detection matters because disease-modifying drugs now exist or are in late-stage trials for several neurodegenerative diseases. Aducanumab and lecanemab target amyloid-beta in Alzheimer’s disease; anti-alpha-synuclein antibodies are in trials for Parkinson’s disease; and antisense oligonucleotides targeting TDP-43 are advancing for frontotemporal dementia. A patient whose blood biomarkers indicate Parkinson’s pathology can now be enrolled in alpha-synuclein trials years before frank motor symptoms appear, potentially preventing or slowing cognitive and motor decline.
This is a fundamental shift from treating symptoms to treating pathology. A concrete example: a 62-year-old woman presenting with mild cognitive impairment and subtle tremor might have been diagnosed with “mild cognitive impairment—likely Alzheimer’s” on clinical grounds alone. A blood biomarker panel showing elevated p-syn and normal phosphorylated tau changes that diagnosis to “cognitive impairment due to Lewy body disease,” prompting referral to Parkinson’s specialists, movement disorder imaging, and potentially enrollment in trials targeting alpha-synuclein. That same woman with accurate early diagnosis may delay or prevent full dementia by years.
WHAT BLOOD TESTS CAN AND CANNOT DO: INTEGRATING BLOOD BIOMARKERS INTO CLINICAL CARE
Blood biomarkers are powerful but not standalone. A single abnormal blood biomarker does not equal a diagnosis; instead, it is one piece of evidence interpreted alongside clinical history, cognitive testing, imaging, and sometimes genetic testing. A patient with elevated p-syn might have Lewy body disease, but other conditions including certain types of Parkinson’s-plus syndromes and inflammatory neurological disorders can also elevate p-syn.
Conversely, some patients with confirmed Lewy body disease on autopsy have normal or borderline blood p-syn levels, suggesting the blood test is sensitive but not 100% specific in all populations. The practical reality is that blood biomarkers accelerate diagnosis by narrowing the differential diagnosis, but they do not replace clinical judgment. A neurologist seeing a 58-year-old with progressive rigidity, slowness, and memory loss will order blood biomarkers to check for Lewy body and Alzheimer’s pathology, but will also order dopamine transporter imaging and neuropsychological testing. The blood test speeds up the process—answers in days instead of months of observation—but remains part of a comprehensive diagnostic workup, not a replacement for it.
THE MAJOR CHALLENGES: STANDARDIZATION, ACCESS, AND TEST VALIDITY ACROSS POPULATIONS
One critical limitation is that blood biomarker testing is not yet standardized across laboratories. A test run at one academic medical center may use different assays, reference ranges, and cutoff values than a test at another center. This means results can vary depending on where the test is performed, and patients transferring between health systems sometimes face the frustration of retesting. The field is moving toward standardization (organizations like the Alzheimer’s Association are supporting validation studies), but as of 2026, this remains an incomplete problem.
Another limitation is population diversity. Most blood biomarker studies have enrolled predominantly white, educated, older populations with access to specialty neurology care. The applicability of biomarker cutoffs and performance to African American, Hispanic, Asian American, and other populations is less well-characterized. A threshold for “abnormal” phosphorylated tau developed in a Northern European cohort may not apply correctly to a Chinese American patient, potentially leading to both over-diagnosis and under-diagnosis depending on the population.
HOW INSURANCE AND ACCESSIBILITY SHAPE WHO CAN GET TESTED
Blood biomarker tests for neurodegeneration are increasingly available but access remains uneven. Some tests are covered by Medicare and major insurers; others are not. The Elecsys p-tau biomarker tests (developed by Roche) are covered by many insurers for Alzheimer’s diagnosis. Newer multi-marker panels like the Lilly Tes or the Washington University tau kinetics panel may be covered only as part of research studies or out-of-pocket.
A patient in a rural area without access to a specialized neurology clinic may not be able to obtain these tests at all, while a patient in an urban academic medical center can access them readily. Cost varies from roughly $500 to $3,000 per test depending on the number of biomarkers measured and whether it is performed through a commercial lab or academic center. Insurance coverage is improving but remains inconsistent, and many patients still face out-of-pocket costs. This creates a two-tier system where well-insured, affluent patients in major cities have rapid access to cutting-edge diagnostic blood biomarkers, while underserved populations lag years behind.
CURRENT CLINICAL USE: WHERE BLOOD BIOMARKERS FIT IN NEUROLOGY TODAY
As of 2026, blood biomarkers for neurodegeneration are most established for Alzheimer’s disease—phosphorylated tau and phosphorylated tau-181 have FDA-authorized laboratory-developed tests (LDTs) and are increasingly used in memory clinics and cognitive aging programs. For Parkinson’s disease and Lewy body dementia, phosphorylated alpha-synuclein testing is gaining traction in research settings and selected academic centers, but clinical utility is still being defined; not all neurologists order it routinely, and insurance coverage is variable. For frontotemporal dementia, blood biomarkers (phosphorylated tau, TDP-43 fragments) show promise in research but are not yet standard clinical practice outside specialty centers.
The practical result is that a 72-year-old with suspected Alzheimer’s disease presenting to a memory clinic will very likely receive a blood biomarker test. A 65-year-old with possible Lewy body dementia may or may not be offered blood p-syn testing depending on whether they see a neurologist with expertise in biomarkers. A 58-year-old with suspected frontotemporal dementia presenting to a community neurology practice may not be tested at all, while the same patient at an academic medical center would be. Blood biomarker testing is expanding rapidly, but implementation remains inconsistent across clinical settings and geographies.
